<DOC>
	<DOC>NCT02265302</DOC>
	<brief_summary>Study to obtain information about the safety and tolerability of BIIL 248 BS, to find the pharmacologically active dose range for the two formulations PSE 1% and WIF tablets by determination of the surrogate marker CD11b (= Mac-1) and to obtain preliminary pharmacokinetic data as well as first information on food effects after administration of the 75 mg WIF tablet in healthy male volunteers</brief_summary>
	<brief_title>Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male subjects as determined by results of screening Age ≥ 21 and ≤ 50 years Broca ≥ 20% and ≤ + 20% Signed written informed consent in accordance with Good Clinical Practice and local legislation Results of the medical examination or laboratory tests that are judged by the clinical investigator to differ significantly from normal clinical values Known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders Known history of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of a drug with a long halflife (≥ 24 hours) within at least one month or less than ten halflives of the respective drug before enrolment in the study Intake of any other drugs which might influence the results of the trial during the week previous to the start of the study Participation in another study with an investigational drug within the last two months preceding this study Smokers (&gt; 5 cigarettes or 2 cigars or 2 pipes/day) Volunteer who is not able to refrain from smoking on study days Alcohol abuse (more than 60 g of alcohol per day) Drug abuse Excessive physical activities (e.g. competitive sports) within the last week before the study Blood donation within the last 4 weeks (≥ 100 ml)</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>